Chapter 22 provides benchmarks for life sciences companies. The category includes pharmaceutical makers, biotechnology product companies, and medical device manufacturers. The 16 respondents in this sample range in size from a minimum of about $50 million to over $40 billion in revenue. (55 pp., 32 fig.)
[Executive Summary]
[Full Study Description]
IT Spending and Staffing Benchmarks 2023/2024: Chapter 22: Life Sciences Subsector Benchmarks
July, 2023
$4,950.00
DISCLAIMER:
Avasant's research and other publications are based on information from the best available sources and Avasant's independent assessment and analysis at the time of publication. Avasant takes no responsibility and assumes no liability for any error/omission or the accuracy of information contained in its research publications. Avasant does not endorse any provider, product or service described in its RadarView™ publications or any other research publications that it makes available to its users, and does not advise users to select only those providers recognized in these publications. Avasant disclaims all warranties, expressed or implied, including any warranties of merchantability or fitness for a particular purpose. None of the graphics, descriptions, research, excerpts, samples or any other content provided in the report(s) or any of its research publications may be reprinted, reproduced, redistributed or used for any external commercial purpose without prior permission from Avasant, LLC. All rights are reserved by Avasant, LLC.